Reier-Nilsen Tonje, Grønneberg Charlotte, Røine Stephanie, Nordlund Björn
The Norwegian Sports Medicine Centre - Football Association, Oslo, Norway.
The Norwegian Olympic Sports Centre, Norwegian Olympic and Paralympic Committee and Confederation of Sports, Oslo, Norway.
Heliyon. 2024 Apr 6;10(8):e29261. doi: 10.1016/j.heliyon.2024.e29261. eCollection 2024 Apr 30.
It is estimated that 65 million people worldwide suffer from long covid (LC). Many LC symptoms are also reported by patients with airflow limitation, used to confirm asthma. The primary aim was to detect airflow limitation in LC patients by a methacholine bronchial provocation test (BPT) and if negative, by evaluation of diurnal variability in forced expiratory flow in 1 second (FEV) over a two-weeks' period. The second aim was to assess responsiveness to asthma treatment on diurnal FEV variability and LC symptoms.
Patients with LC for at least six months were recruited in this open diagnostic study. Burden of LC symptoms were reported on a 10-point Likert scale (0 = not troubled, 10 = extremely troubled) at inclusion and after three weeks' asthma treatment. A positive methacholine BPT was defined by an accumulated provocation dose (PD)<8 μmol causing 20% fall in FEV. App-based spirometer was used for diurnal FEV variability, deemed positive by diurnalvariability in FEV ≥12%.
Airflow limitation was documented by positive methacholine BPT in 8/30 (27%), or by excessive diurnal variability in FEV in 21/22 (95%) of the BPT negative LC patients. One patient dropped out due to personal issues. Three weeks' asthma treatment normalised mean diurnal FEV variability from 18.0% to 7.3%, p < 0.001. Significant reductions were observed for fatigue and dyspnoea, from 8.3 to 6.1, p < 0.001, and 3.0 to 0, p < 0.001, respectively.
This study indicate that airflow limitation may be detected in many LC patients if evaluation of diurnal variability in FEV is included in the diagnostics.
据估计,全球有6500万人患有新冠后综合征(LC)。气流受限患者也报告了许多新冠后综合征症状,气流受限用于确诊哮喘。主要目的是通过乙酰甲胆碱支气管激发试验(BPT)检测新冠后综合征患者的气流受限情况,若结果为阴性,则通过评估两周内一秒用力呼气流量(FEV)的日变化率来检测。第二个目的是评估哮喘治疗对FEV日变化率和新冠后综合征症状的反应性。
在这项开放性诊断研究中招募了患有新冠后综合征至少六个月的患者。在纳入研究时以及哮喘治疗三周后,采用10分制李克特量表(0 = 无困扰,10 = 极度困扰)报告新冠后综合征症状的负担。乙酰甲胆碱BPT阳性定义为累积激发剂量(PD)<8 μmol且FEV下降20%。基于应用程序的肺活量计用于FEV日变化率的检测,若FEV日变化率≥12%则判定为阳性。
8/30(27%)的患者通过乙酰甲胆碱BPT阳性记录到气流受限,或在21/22(95%)的BPT阴性新冠后综合征患者中通过FEV的过度日变化率记录到气流受限。一名患者因个人问题退出研究。哮喘治疗三周后,平均FEV日变化率从18.0%降至7.3%,p < 0.001。疲劳和呼吸困难症状显著减轻,分别从8.3降至6.1,p < 0.001,以及从3.0降至0,p < 0.001。
本研究表明,如果在诊断中纳入FEV日变化率的评估,可能会在许多新冠后综合征患者中检测到气流受限。